SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aviron
AVIR 3.375+1.7%Nov 11 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biodoc who wrote (242)6/1/1998 9:29:00 AM
From: SJS   of 645
 
Very helpful. I went back to the press release, and I didn't pick up the subtlety of this comment the first time:

RelenzaTM, the first effective treatment for all strains of influenza, was filed with the Therapeutic Goods Administration for marketing approval in Australia on 30 March 1998,after Phase III clinical trials were conducted in the Southern Hemisphere during the last flu season.

Appreciate the explanation.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News